Sign In
Buy PTGX
$95.41
+2.18 (+2.34%)
At Close: Jun 03, 2026
Protagonist Therapeutics, Inc. (PTGX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
02:02pm, Thursday, 12'th Mar 2026
Protagonist Therapeutics, Inc. (PTGX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
OSAKA, Japan & CAMBRIDGE, Mass. & NEWARK, Calif.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) today announced that the U.S. Food an
Citigroup Inc. Has $10.14 Million Stake in Protagonist Therapeutics, Inc. $PTGX
03:51am, Sunday, 01'st Mar 2026
Citigroup Inc. grew its position in Protagonist Therapeutics, Inc. (NASDAQ: PTGX) by 95.7% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. Th
CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
05:15pm, Wednesday, 25'th Feb 2026
(This release updates the release that posted earlier on February 25, 2026 to update the sub headlines.) NDA for rusfertide submitted to the US Food and Drug Administration (FDA), with potential appro
Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
04:05pm, Wednesday, 25'th Feb 2026
NDA for rusfertide submitted to the US Food and Drug Administration (FDA), with potential approval and launch this year Company expects to opt-out of the 50:50 profit and loss sharing arrangement for
Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit
03:28pm, Wednesday, 25'th Feb 2026
Hedge fund BVF sold 2,560,916 shares of PTGX in the fourth quarter. As a result, the quarter-end position value decreased by $170.12 million.
Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in March 2026
07:30am, Tuesday, 24'th Feb 2026
NEWARK, CA / ACCESS Newswire / February 24, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D.
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Consensus Recommendation of “Moderate Buy” by Analysts
01:48am, Thursday, 19'th Feb 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the thirteen ratings firms that are presently covering the firm, Marketbeat repor
Protagonist Therapeutics Director Sells 20,000 Shares Amid Strong Stock Performance
03:38am, Monday, 16'th Feb 2026
A director for Protagonist Therapeutics sold 20,000 shares for a transaction value of approximately $1.7 million on Feb. 6, 2026. The transaction involved the exercise of stock options, after which th
Protagonist Therapeutics Chief Medical Officer Sells PTGX 9,514 Shares for $784K to Cover Taxes
12:25am, Sunday, 01'st Feb 2026
Arturo Molina sold 9,514 directly on Jan. 20, 2026, generating a transaction value of approximately $784,700 at a reported price of $82.48 per share. This sale represented 8.91% of Dr. Molina's direct
Protagonist Therapeutics (NASDAQ:PTGX) Insider Arturo Md Molina Sells 5,000 Shares
06:20am, Wednesday, 28'th Jan 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX - Get Free Report) insider Arturo Md Molina sold 5,000 shares of Protagonist Therapeutics stock in a transaction dated Tuesday, January 27th. The shares we
Protagonist Therapeutics (NASDAQ:PTGX) CEO Dinesh Ph Patel Sells 4,068 Shares
06:20am, Wednesday, 28'th Jan 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX - Get Free Report) CEO Dinesh Ph Patel sold 4,068 shares of the business's stock in a transaction dated Tuesday, January 27th. The shares were sold at an a
Protagonist Therapeutics (NASDAQ:PTGX) Insider Arturo Md Molina Sells 13,151 Shares of Stock
05:35am, Wednesday, 28'th Jan 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX - Get Free Report) insider Arturo Md Molina sold 13,151 shares of the firm's stock in a transaction dated Friday, January 23rd. The stock was sold at an av
Protagonist Therapeutics (NASDAQ:PTGX) CFO Asif Ali Sells 46,203 Shares of Stock
05:35am, Wednesday, 28'th Jan 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX - Get Free Report) CFO Asif Ali sold 46,203 shares of the stock in a transaction that occurred on Tuesday, January 27th. The shares were sold at an average
Protagonist Therapeutics (NASDAQ:PTGX) CEO Dinesh Ph Patel Sells 19,315 Shares
05:34am, Wednesday, 28'th Jan 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX - Get Free Report) CEO Dinesh Ph Patel sold 19,315 shares of the company's stock in a transaction dated Friday, January 23rd. The shares were sold at an av
